BaroFold, Inc. Grants Exclusive License for Interferon Beta Products Developed Using PreEMT(TM) Technology to Nuron Biotech
5/17/2010 9:21:03 AM
AURORA, Colo.--(BUSINESS WIRE)--BaroFold, Inc. today announced that it has entered into an agreement to exclusively license its PreEMT™ Technology to Nuron Biotech for the development of BaroFeron™ and follow-on interferon beta products. BaroFeron is a proprietary recombinant human interferon beta being developed for the treatment of multiple sclerosis. Specific terms of the agreement are not disclosed.
comments powered by